Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 25, 2009

Implicit Licenses mAb from Lilly for Development in Acute Lung Injury

  • Implicit Bioscience acquired Eli Lilly’s clinical-stage mAb called IC14 to develop the molecule as a treatment for acute lung injury. Lilly received a combining of cash and stock and will earn a royalty.

    Implicit intends to initiate Phase II development this year and recently completed a capital round in which its shareholders added AU$6 million, or $3.9 million, to its cash balance.

    “We seek to mitigate product risk through acquiring clinical-stage programs with proven safety and defined opportunities in immunological indications,” explains Garry Redlich, Implicit CEO. “We further mitigate risk by seeking nondilutive third-party funding to support a portion of our development expense.”

    Lilly obtained IC14 through its $2.3 billion takeover of Icos. Icos had been investigating the drug in severe sepsis.
    Johnson and Johnson, The Scripps Research Institute, The Rockefeller University, and Lilly are parties to a separate agreement with Implicit, which governs the payment to them by Implicit of milestones and royalties on IC14 development and commercialization.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »